Pharmaceuticals, Biotechnology and Life Sciences
Sosei Group Corporationhas partnered up with Takeda to work on novel molecules, including small molecules and biologics, that modulate G protein-coupled receptor (“GPCR”) targets.
Mylan’s second quarter performance was strong as the company has delivered or exceeded on expectations across all financial metrics, the company’s CEO Heather Bresch said in a press release Monday.
Proteostasis Therapeutics has started with the phase 2 study of cystic fibrosis treatment by dosing the first patient, after a successful Phase 1 test of PTI’s combinations.
BioCity, and Oxford AHSN are launching a new Accelerator Programme in Berkshire and South Oxfordshire to catalyse growth in Thames Valley’s world-class health and life sciences cluster by supporting the development of start-ups, spin-outs and growth companies across the region’s research, clinical and commercial base.
Inovio Pharmaceuticals published its positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus…
ImaginAb has started the clinical trial of its lead product, CD8 tracer Zr-Df-IAB22M2C, a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells.
Immix Biopharma, said Tuesday it got a letter from the FDA authorizing it to expand its phase 1b/2a clinical trial of…
Actinium Pharmaceuticals underlines half of patients treated in the pivotal Phase 3 SIERRA testing Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia is the only randomized Phase 3 trial that offers BMT or bone marrow transplant as an option for older patients with active, relapsed or refractory AML or acute myeloid leukemia.
Camurus said Monday that the United States District Court for the District of Columbia granted Braeburn’s motion for summary judgement, vacating the U.S. Food and Drug Administration’s (FDA) decision to block final market approval of Brixadi Monthly.
MedPharm Ltd, a leader in topical and transdermal drug delivery, has expanded its relationship with the NASDAQ listed biopharmaceutical company Novan Inc.